Drug Trial Radar · NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
258
Planned (sponsor's estimate)
Start
Jan 23, 2025
Primary completion
Nov 30, 2029
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Conditions
- Chronic Lymphocytic Leukemia
- CLL
- Mantle Cell Lymphoma
- MCL
Interventions
SonrotoclaxDrug
Administered orally
ZanubrutinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experience Tumor Lysis Syndrome (TLS)Time frame: Up to approximately 4 months
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia · Recruiting
Genesiscare St Andrews
Adelaide, South Australia, Australia · Recruiting
Cabrini Hospital Malvern
Malvern, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Rockingham Hospital
Cooloongup, Western Australia, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia Celular
São Paulo, Brazil · Recruiting
Hospital Santa Rita de Cassia Afecc
Vitória, Brazil · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Chu Dijon
Dijon, France · Recruiting
Chu Montpellier Hopital Saint Eloi
Montpellier, France · Recruiting
Iuct Oncopole
Toulouse, France · Recruiting
Queen Elizabeth Hospital
Birmingham, United Kingdom · Recruiting
St Jamess University Hospital
Leeds, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.